Company news
Ibio, Inc. (NASDAQ:IBIO) news
Ibio, Inc. news releases on 6ix. Latest, Sep 27, 2023: iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
Press releases — page 2
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
September 26, 2023
iBio Announces Amendment to Credit Agreement with Woodforest
September 20, 2023
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
June 26, 2023
iBio Forges Research Collaboration with the National Institutes of Health
June 11, 2023
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
April 3, 2023
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
March 30, 2023
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
February 15, 2023
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
January 4, 2023
iBio Announces Closing of $3.5 Million Underwritten Public Offering
December 8, 2022
iBio Announces Proposed Underwritten Public Offering
December 5, 2022
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
December 5, 2022
iBio Announces CEO Departure
December 1, 2022
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
September 26, 2022
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
September 20, 2022
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
August 15, 2022
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
May 8, 2022
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
May 1, 2022
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
February 13, 2022
iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
January 25, 2022
iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
December 21, 2021
iBio Announces Partial Adjournment of Annual Meeting to December 22
December 9, 2021
iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
November 14, 2021
iBio Acquires FastPharming Manufacturing Facility®
November 2, 2021
iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
October 25, 2021
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
September 26, 2021
iBio Appoints William D. Clark to its Board of Directors
August 25, 2021
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
July 14, 2021
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
July 7, 2021
iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update
May 16, 2021
iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021
May 9, 2021
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program
May 5, 2021
iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement
May 3, 2021
iBio Appoints Robert M. Lutz as Chief Financial & Business Officer
February 15, 2021
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
December 27, 2020
iBio Announces Closing of its Public Offering of Common Stock
December 9, 2020
iBio Announces Pricing of $35 Million Public Offering of Common Stock
December 7, 2020
iBio Announces Proposed Public Offering of Common Stock
December 6, 2020
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
November 30, 2020
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
November 23, 2020
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2020
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer
November 2, 2020
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors
October 14, 2020
Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors
October 14, 2020
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
October 13, 2020
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020
October 12, 2020
iBio Regains Compliance with NYSE American Continued Listing Standards
October 4, 2020
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
September 8, 2020
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic
August 27, 2020
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
August 9, 2020
iBio Announces Second COVID-19 Vaccine Program
June 3, 2020